AMEX:MYO

Stock Analysis Report

Executive Summary

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has Myomo's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9.6%

MYO

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

-63.8%

MYO

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: MYO underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: MYO underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

MYOIndustryMarket
7 Day9.6%2.0%1.8%
30 Day-14.3%-1.8%-0.7%
90 Day-13.1%-0.5%0.06%
1 Year-63.8%-63.8%14.2%13.3%9.7%7.3%
3 Yearn/a70.5%65.3%46.3%36.9%
5 Yearn/a127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Myomo's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Myomo undervalued compared to its fair value and its price relative to the market?

1.61x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate MYO's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate MYO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MYO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: MYO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate MYO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYO is good value based on its PB Ratio (1.6x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Myomo forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

44.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MYO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MYO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MYO's revenue (52.4% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: MYO's revenue (52.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if MYO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Myomo performed over the past 5 years?

-26.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MYO is unprofitable, and losses have increased over the past 5 years at a rate of -26.7% per year.

Accelerating Growth: Unable to compare MYO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: MYO has a negative Return on Equity (-147.82%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MYO is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MYO is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Myomo's financial position?


Financial Position Analysis

Short Term Liabilities: MYO's short term assets ($8.2M) exceeds its short term liabilities ($1.4M)

Long Term Liabilities: MYO has no long term liabilities


Debt to Equity History and Analysis

Debt Level: MYO is debt free.

Reducing Debt: MYO had no debt 5 years ago.


Balance Sheet

Inventory Level: MYO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MYO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MYO has less than a year of cash runway if free cash flow continues to reduce at historical rates of -45.6% each year


Next Steps

Dividend

What is Myomo's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MYO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MYO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MYO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Myomo's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Paul Gudonis (64yo)

8.3yrs

Tenure

US$537,592

Compensation

Mr. Paul R. Gudonis has been the Chief Executive Officer and President of Myomo, Inc. since July 2011 and February 2017 respectively. Mr. Gudonis served as President of United States Foundation For Inspira ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Paul's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.2yrs

Average Tenure

63.5yo

Average Age

Experienced Management: MYO's management team is considered experienced (2.2 years average tenure).


Board Age and Tenure

3.2yrs

Average Tenure

68yo

Average Age

Experienced Board: MYO's board of directors are considered experienced (3.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Steve Sanghi (63yo)

    • Tenure: 0yrs
    • Compensation: US$65.00k
  • David Henry (58yo)

    Chief Financial Officer

    • Tenure: 0.7yrs
  • Paul Gudonis (64yo)

    Chairman

    • Tenure: 8.3yrs
    • Compensation: US$537.59k
  • Ralph Goldwasser (71yo)

    Consultant

    • Tenure: 0.7yrs
    • Compensation: US$398.70k
  • Cliff Conneighton (69yo)

    Chief Marketing Officer

    • Tenure: 2.2yrs
  • Jon Naft (54yo)

    • Tenure: 7.5yrs
    • Compensation: US$356.85k
  • Brandon Green (72yo)

    Chief Medical Officer

    • Tenure: 2.3yrs
  • Micah Mitchell (43yo)

    Chief Commercial Officer

    • Tenure: 1.3yrs

Board Members

  • Paul Gudonis (64yo)

    Chairman

    • Tenure: 8.3yrs
    • Compensation: US$537.59k
  • Tom Kirk (73yo)

    Lead Independent Director

    • Tenure: 3yrs
    • Compensation: US$70.00k
  • Tom Crowley (72yo)

    Independent Director

    • Tenure: 7.6yrs
    • Compensation: US$70.00k
  • Amy Knapp (64yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$70.00k
  • Ross Zafonte

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Steve Kirshblum

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Fred Nahm

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Steve Wolf

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Diane Atkins

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Coleman Nee

    Chairman of Veteran Advisory Board

    • Tenure: 0yrs

Company Information

Myomo, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Myomo, Inc.
  • Ticker: MYO
  • Exchange: AMEX
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$11.473m
  • Shares outstanding: 17.14m
  • Website: https://www.myomo.com

Number of Employees


Location

  • Myomo, Inc.
  • One Broadway
  • 14th Floor
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYOAMEX (NYSE MKT LLC)YesCommon StockUSUSDJun 2017
0M6BST (Boerse-Stuttgart)YesCommon StockDEEURJun 2017

Biography

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectri ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 00:43
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.